IPO
Filter News
Found 17,224 articles
-
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - May 21, 2021
5/21/2021
Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan.
-
Atrion Corporation Declares Quarterly Cash Dividend - May 21, 2021
5/21/2021
Atrion Corporation announced that its Board of Directors declared a quarterly dividend of $1.75 per share on its outstanding shares of Common Stock.
-
Evofem Biosciences Announces Closing of $50 Million Public Offering - May 21, 2021
5/21/2021
Evofem Biosciences, Inc. announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock and accompanying two-year warrants to purchase an aggregate of up to 50 million shares of common stock.
-
Allarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics
5/21/2021
US $20 million investment by 3iFund is conditioned upon completion of the recapitalization into a newly organized Delaware holding company (Allarity Therapeutics, Inc.) and a listing of its common stock on the U.S. Nasdaq Stock Market
-
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
5/20/2021
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today the pricing of an underwritten public offering of 19,354,840 shares of its common stock, at a price to the public of $3.10 per share.
-
Kane Biotech to Release First Quarter 2021 Financial Results on May 27 – Conference Call to Follow
5/20/2021
Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its first quarter 2021 financial results after market close on Thursday, May 27, 2021.
-
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
5/20/2021
Zealand Pharma A/S, a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 2,000 divided into 2,000 new shares with a nominal value of DKK 1 each.
-
BrainsWay Reports First Quarter 2021 Financial Results and Operational Highlights
5/20/2021
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, reported first quarter 2021 financial results and provided an operational update.
-
NeuPath Health Reports 2021 First Quarter Results
5/20/2021
NeuPath Health Inc., owner and operator of a network of clinics that deliver category-leading treatment for chronic pain, as well as spinal injuries, sports-related injuries, and concussions, announced its financial and operating results for the three months ended March 31, 2021.
-
ATI Physical Therapy Reports First Quarter 2021 Financial Results
5/20/2021
ATI Physical Therapy, one of the nation's largest providers of outpatient physical therapy services, reported financial results for the first quarter of 2021 ended March 31, 2021.
-
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update
5/20/2021
Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma
-
Ansys Ushers in a New Era of Online Learning with Cornell Engineering
5/20/2021
Ansys and Cornell University join forces to create a dynamic engineering curriculum, enabling nearly every engineering student to master simulation
-
BioSyent Schedules Q1 2021 Earnings Release for May 27, 2021
5/20/2021
BioSyent Inc. will be reporting its financial results for the three months ended March 31, 2021 on Thursday, May 27, 2021 at 8:00am EDT.
-
Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates
5/20/2021
Entera Bio Ltd., a leader in the development of orally delivered large molecule therapeutics, announced financial and operating results for the quarter ended March 31, 2021.
-
HAYA Therapeutics Completes CHF 18 Million Seed Financing To Advance Anti-fibrotic Therapies Targeting Long Non-coding RNAs
5/20/2021
HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs, announced the successful closing of its CHF 18 million seed round.
-
NHI Provides Business Update - May 20, 2021
5/20/2021
National Health Investors, Inc. provided a business update regarding its monthly contractual cash collections.
-
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
5/20/2021
IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023
-
Luminex Corporation Declares Second Quarter Cash Dividend - May 20, 2021
5/20/2021
Luminex Corporation announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0.10 per share of common stock payable on July 8, 2021 to stockholders of record as of the close of business June 17, 2021.
-
Quest Diagnostics Declares Quarterly Cash Dividend - May 20, 2021
5/20/2021
Quest Diagnostics, the world's leading provider of diagnostic information services, announced that its Board of Directors declared a quarterly cash dividend of $0.62 per share, payable on July 21, 2021 to shareholders of record of Quest Diagnostics common stock on July 7, 2021.
-
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - May 20, 2021
5/20/2021
Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company's 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.